JP4204783B2 - レボドパ／カルビドパ／エンタカポン医薬製剤 - Google Patents

レボドパ／カルビドパ／エンタカポン医薬製剤 Download PDF

Info

Publication number
JP4204783B2
JP4204783B2 JP2001507476A JP2001507476A JP4204783B2 JP 4204783 B2 JP4204783 B2 JP 4204783B2 JP 2001507476 A JP2001507476 A JP 2001507476A JP 2001507476 A JP2001507476 A JP 2001507476A JP 4204783 B2 JP4204783 B2 JP 4204783B2
Authority
JP
Japan
Prior art keywords
carbidopa
entacapone
levodopa
pharmaceutically acceptable
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2001507476A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003503454A5 (enExample
JP2003503454A (ja
Inventor
カッリオイネン、サリ
ケルビネン、ラッセ
ラークソネン、マルヤ
リンツラークソ、ヤルモ
ニスカネン、メルビ
パルタネン、マルヤ
リタラ、マルヤ
バヘルブオ、カリ
ビルッキ、マッチ
Original Assignee
オリオン コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8554988&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4204783(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by オリオン コーポレーション filed Critical オリオン コーポレーション
Publication of JP2003503454A publication Critical patent/JP2003503454A/ja
Publication of JP2003503454A5 publication Critical patent/JP2003503454A5/ja
Application granted granted Critical
Publication of JP4204783B2 publication Critical patent/JP4204783B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2001507476A 1999-06-30 2000-06-29 レボドパ／カルビドパ／エンタカポン医薬製剤 Expired - Lifetime JP4204783B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI991485A FI109453B (fi) 1999-06-30 1999-06-30 Farmaseuttinen koostumus
FI991485 1999-06-30
PCT/FI2000/000593 WO2001001984A1 (en) 1999-06-30 2000-06-29 Levodopa / carbidopa / entacapone pharmaceutical preparation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008063280A Division JP4885896B2 (ja) 1999-06-30 2008-03-12 レボドパ／カルビドパ／エンタカポン医薬製剤

Publications (3)

Publication Number Publication Date
JP2003503454A JP2003503454A (ja) 2003-01-28
JP2003503454A5 JP2003503454A5 (enExample) 2007-06-07
JP4204783B2 true JP4204783B2 (ja) 2009-01-07

Family

ID=8554988

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2001507476A Expired - Lifetime JP4204783B2 (ja) 1999-06-30 2000-06-29 レボドパ／カルビドパ／エンタカポン医薬製剤
JP2008063280A Expired - Lifetime JP4885896B2 (ja) 1999-06-30 2008-03-12 レボドパ／カルビドパ／エンタカポン医薬製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008063280A Expired - Lifetime JP4885896B2 (ja) 1999-06-30 2008-03-12 レボドパ／カルビドパ／エンタカポン医薬製剤

Country Status (42)

Country Link
US (2) US6500867B1 (enExample)
EP (1) EP1189608B1 (enExample)
JP (2) JP4204783B2 (enExample)
KR (1) KR100905428B1 (enExample)
CN (1) CN1168440C (enExample)
AR (1) AR033796A1 (enExample)
AT (1) ATE245417T1 (enExample)
AU (1) AU765932B2 (enExample)
BG (1) BG65364B1 (enExample)
BR (2) BRPI0011867B8 (enExample)
CA (1) CA2378469C (enExample)
CO (1) CO5180579A1 (enExample)
CZ (2) CZ304416B6 (enExample)
DE (1) DE60004052T2 (enExample)
DK (1) DK1189608T3 (enExample)
EA (1) EA004503B1 (enExample)
EE (1) EE05473B1 (enExample)
ES (1) ES2203495T3 (enExample)
FI (1) FI109453B (enExample)
FR (1) FR2797587A1 (enExample)
GE (1) GEP20043314B (enExample)
HK (1) HK1047040B (enExample)
HR (1) HRP20020088B1 (enExample)
HU (1) HU230395B1 (enExample)
IL (1) IL146807A (enExample)
IT (1) ITMI20001450A1 (enExample)
ME (1) ME00520B (enExample)
MX (1) MXPA01013167A (enExample)
MY (1) MY127685A (enExample)
NO (2) NO330260B1 (enExample)
NZ (1) NZ515780A (enExample)
PE (1) PE20010399A1 (enExample)
PL (1) PL197818B1 (enExample)
PT (1) PT1189608E (enExample)
RS (1) RS50368B (enExample)
SI (1) SI1189608T1 (enExample)
SK (1) SK286451B6 (enExample)
TR (1) TR200103763T2 (enExample)
TW (1) TWI241187B (enExample)
UA (1) UA75047C2 (enExample)
WO (1) WO2001001984A1 (enExample)
ZA (1) ZA200109868B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008156373A (ja) * 1999-06-30 2008-07-10 Orion Corp レボドパ／カルビドパ／エンタカポン医薬製剤

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040166159A1 (en) * 2002-05-29 2004-08-26 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa
US7094427B2 (en) * 2002-05-29 2006-08-22 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US20030224045A1 (en) * 2002-05-29 2003-12-04 Chien-Hsuan Han Combination immediate release sustained release levodopa/carbidopa dosage forms
US20050147670A1 (en) * 2002-05-29 2005-07-07 Impax Laboratories Inc. Oral disintegrating dosage forms
US20060013875A1 (en) * 2002-05-29 2006-01-19 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US20040006072A1 (en) * 2002-06-25 2004-01-08 Franz Robert M. Sustained-release alprazolam composition
US20040180086A1 (en) * 2002-10-11 2004-09-16 Zebunnissa Ramtoola Gastro-retentive levodopa delivery form
AR044007A1 (es) 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
EP1588704A1 (en) 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
SE0401842D0 (sv) 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
WO2006037061A2 (en) * 2004-09-28 2006-04-06 Farouk Karoum Compositions and methods of using d-dopa to treat parkinson's disease
US20060173074A1 (en) 2004-11-10 2006-08-03 Juha Ellmen Treatment of restless legs syndrome
AU2012216377C1 (en) * 2005-06-08 2013-10-10 Orion Corporation Oral dosage form
EP2308487A1 (en) * 2005-06-08 2011-04-13 Orion Corporation An entacapone-containing oral dosage form
US20070003621A1 (en) * 2005-06-23 2007-01-04 Spherics, Inc. Dosage forms for movement disorder treatment
MY148644A (en) 2005-07-18 2013-05-15 Orion Corp New pharmaceutical compounds
US8168793B2 (en) * 2005-07-26 2012-05-01 Portela & Ca., S.A. Nitrocatechol derivatives as COMT inhibitors
US8877802B2 (en) * 2005-07-28 2014-11-04 Duke Univerity Antiparkinsonian action of phenylisopropylamines
WO2007034024A2 (en) * 2005-09-21 2007-03-29 Orion Corporation Treatment of symptoms of parkinson' s disease
US20070178149A1 (en) * 2005-11-07 2007-08-02 Moshe Flashner-Barak Levodopa compositions
EP1954256A2 (en) * 2005-11-09 2008-08-13 Torrent Pharmaceuticals Ltd Pharmaceutical composition comprising a compound having a catechol moiety and an alkalising agent
GB2429645A (en) * 2006-03-10 2007-03-07 Sekhsaria Chemicals Ltd Solid pharmaceutical composition comprising a COMT inhibitor, a starch and a wetting agent
CN100384411C (zh) * 2006-03-17 2008-04-30 北京科信必成医药科技发展有限公司 卡左双多巴口腔崩解片
WO2007113371A1 (en) * 2006-03-31 2007-10-11 Iprbox Oy Pharmaceutical composition and preparation method thereof
EP1845097A1 (en) 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
EP1870097A1 (en) * 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
US8106056B2 (en) * 2006-06-16 2012-01-31 Solvay Pharmaceuticals B.V. Combination preparations comprising bifeprunox and a dopamine agonist
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
WO2008053297A2 (en) * 2006-10-30 2008-05-08 Wockhardt Research Centre Pharmaceutical compositions comprising entacapone, levodopa, and carbidopa
US20100316712A1 (en) * 2006-12-22 2010-12-16 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
EP2114374A4 (en) * 2006-12-27 2011-03-23 Wockhardt Research Center PHARMACEUTICAL COMPOSITIONS OF ENTACAPONE
EP1946756A1 (en) * 2007-01-17 2008-07-23 Revotar Biopharmaceuticals AG Use of entacapone in cosmetic, dermatological and pharmaceutical compositions
PL2481410T3 (pl) 2007-01-31 2017-03-31 Bial - Portela & Ca., S.A. Pochodne nitrokatecholu jako inhibitory COMT podawane w określonym schemacie dawkowania
US20110171275A1 (en) * 2007-08-20 2011-07-14 Team Academy Of Pharmaceutical Science Gastroretentive drug delivery system, preparation method and use thereof
MX2010008711A (es) 2008-02-06 2011-05-03 Wockhardt Ltd Composiciones farmaceuticas de entacapona, levopoda y carbidopa, con biodisponibilidad mejorada.
US8728517B2 (en) * 2008-02-06 2014-05-20 Wockhardt Ltd. Pharmaceutical compositions of entacapone co-micronized with sugar alcohols
CL2009000628A1 (es) 2008-03-17 2010-04-09 Bial Portela & Companhia S A Forma cristalina de 5-[3-(2,5-dicloro-4,6-dimetil-1-oxi-piridin-3-il)-[1,2,4]oxadiazol-5-il]-3-nitrobenceno-1,2-diol, composicion farmaceutica que la comprende, proceso para obtenerla y su uso para tratar trastornos del animo, enfermedad de parkinson y trastornos parkinsonianos, alteraciones gastrointestinales, entre otros.
KR20110046555A (ko) 2008-08-22 2011-05-04 욱크하르트 리서치 센터 레보도파, 카비도파 및 엔타카폰 또는 이의 염을 포함하는 단일 단위 경구 투여 약학 조성물
BRPI0916922A2 (pt) * 2008-08-22 2015-11-24 Wockhardt Research Center composição farmacêutica de liberação prolongada de entacapona ou sais da mesma
TR200806646A2 (tr) * 2008-09-03 2009-06-22 Dr. F. Fri̇k İlaç San. Ve Ti̇c. A.Ş. Entakapon, levodopa ve karbidoba içeren farmasötik kombinasyonlar
EP2233131A1 (en) 2009-03-23 2010-09-29 Laboratorios Lesvi, S.L. Pharmaceutical composition containing levodopa, entacapone and carbidopa
US9132094B2 (en) 2009-04-01 2015-09-15 Bial—Portela & Ca, S.A. Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof
AU2010250766B2 (en) 2009-05-19 2015-04-09 Neuroderm Ltd Compositions for continuous administration of dopa decarboxylase inhibitors
JP5718937B2 (ja) * 2009-12-25 2015-05-13 イノファーマックス インコーポレイテッド パーキンソン病を治療するための医薬組成物及びその調製方法
CN102781424B (zh) 2010-03-04 2016-03-30 奥赖恩公司 左旋多巴、卡比多巴和恩他卡朋用于治疗帕金森病的应用
DE102010023828A1 (de) * 2010-06-15 2011-12-15 IIP - Institut für industrielle Pharmazie, Forschungs- und Entwicklungsgesellschaft mbH Pharmazeutisches Präparat, welches Entacapon, Levodopa und Carbidopa enthält
NZ610911A (en) * 2010-11-15 2015-02-27 Neuroderm Ltd Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
EP2508174A1 (en) 2011-04-06 2012-10-10 Ljiljana Sovic Brkicic Pharmaceutical composition
WO2012147099A1 (en) * 2011-04-25 2012-11-01 Suven Nishtaa Pharma Pvt. Ltd. Pharmaceutical compositions of levodopa, carbidopa and entacapone
KR101807907B1 (ko) * 2011-04-26 2017-12-11 이노파막스, 인크. 엔타카폰의 조성물
PT2791134T (pt) 2011-12-13 2019-12-18 BIAL PORTELA & Cª S A Composto químico útil como intermediário para a preparação de um inibidor de catecol-o-metiltransferase
TR201204839A2 (tr) 2012-04-25 2012-12-21 Ali̇ Rai̇f İlaç Sanayi̇ A.Ş. Uzatılmış salım sağlayan levodopa karbıdopa entakapon içeren tablet formülasyonu.
US9999674B2 (en) 2012-06-05 2018-06-19 Neuroderm, Ltd. Compositions comprising apomorphine and organic acids and uses thereof
JP6472391B2 (ja) * 2013-03-13 2019-02-20 ニューロダーム リミテッドＮｅｕｒｏｄｅｒｍ Ｌｔｄ パーキンソン病の治療方法
EP2799065A1 (en) * 2013-04-30 2014-11-05 Deva Holding Anonim Sirketi Levodopa carbidopa entacapone pharmaceutical formulations
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
ES2823000T3 (es) 2013-10-07 2021-05-05 Impax Laboratories Llc Formulaciones muco-adhesivas de liberación controlada de levodopa y/o ésteres de levodopa y usos de las mismas
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
MX2016011837A (es) 2014-03-13 2017-04-27 Neuroderm Ltd Composiciones de inhibidores de la dopa decarboxilasa.
JP6622310B2 (ja) 2014-09-04 2019-12-18 ロブソル・ファーマシューティカルズ・アクチボラグＬｏｂｓｏｒ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ａｋｔｉｅｂｏｌａｇ レボドパ、ドーパミン脱炭酸酵素阻害薬およびｃｏｍｔ阻害薬を含む医薬組成物ならびにその投与方法
RU2017120184A (ru) 2014-11-28 2018-12-28 БИАЛ - ПОРТЕЛА ЭНД Ка, С.А. Лекарства для замедления течения болезни паркинсона
WO2016101969A1 (en) 2014-12-23 2016-06-30 Pharmathen S.A. Levodopa/carbidopa/entacapone pharmaceutical preparation and method for preparing the same
WO2017039525A1 (en) 2015-09-04 2017-03-09 Lobsor Pharmaceuticals Aktiebolag Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor
WO2018011181A1 (en) * 2016-07-11 2018-01-18 Contera Pharma Aps Pulsatile drug delivery system for treating morning akinesia
ES2895054T3 (es) 2016-08-18 2022-02-17 Ilko Ilac Sanayi Ve Ticaret Anonim Sirketi Fórmula de comprimido antiparkinson con perfil de disolución mejorado
WO2019145773A1 (en) 2017-12-15 2019-08-01 Nos Life Sciences Corporation Liposomal-encapsulated formulations
KR20200136008A (ko) 2018-03-23 2020-12-04 롭서 파마슈티컬스 악티에볼라그 신경퇴행성 장애의 치료를 위한 약제학적 조성물의 연속 투여
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen
JP2024501235A (ja) 2020-12-22 2024-01-11 アムニール ファーマスーティカルズ エルエルシー レボドパ投薬レジメン
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4190672A (en) 1978-09-01 1980-02-26 Stanley Fahn Method and compositions of treating Parkinsonisms with levodopa and 3',4'-dihydroxy-2-methylisopropiophenone
GB8521350D0 (en) * 1985-08-28 1985-10-02 Euro Celtique Sa Analgesic composition
US5236952A (en) 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
NZ220599A (en) * 1986-06-16 1990-10-26 Merck & Co Inc Controlled release oral dosage formulation of carbidopa and levodopa
US5283352A (en) 1986-11-28 1994-02-01 Orion-Yhtyma Oy Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same
DE4101873C2 (de) 1991-01-23 1993-12-09 Isis Pharma Gmbh Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände
US5888534A (en) 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
GB2321190B (en) * 1997-01-16 2000-09-20 Britannia Pharmaceuticals Ltd Pharmaceutical composition
US6599530B2 (en) 1998-09-14 2003-07-29 Orion Corporation Oral compacted composition comprising catechol derivatives
FI109453B (fi) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008156373A (ja) * 1999-06-30 2008-07-10 Orion Corp レボドパ／カルビドパ／エンタカポン医薬製剤

Also Published As

Publication number Publication date
CN1358090A (zh) 2002-07-10
ZA200109868B (en) 2003-05-28
BRPI0011867B8 (pt) 2021-05-25
MXPA01013167A (es) 2002-07-02
CO5180579A1 (es) 2002-07-30
FI109453B (fi) 2002-08-15
KR100905428B1 (ko) 2009-06-30
GEP20043314B (en) 2004-02-10
NZ515780A (en) 2004-06-25
HK1047040A1 (en) 2003-02-07
SK19232001A3 (sk) 2002-06-04
PL352775A1 (en) 2003-09-08
HUP0202273A2 (en) 2002-10-28
NO20016203L (no) 2002-02-25
AU765932B2 (en) 2003-10-02
CA2378469C (en) 2009-10-06
EA004503B1 (ru) 2004-04-29
US6797732B2 (en) 2004-09-28
HRP20020088B1 (hr) 2007-05-31
EP1189608B1 (en) 2003-07-23
RS50368B (sr) 2009-11-10
WO2001001984A1 (en) 2001-01-11
KR20020010155A (ko) 2002-02-02
US20030017201A1 (en) 2003-01-23
ITMI20001450A0 (it) 2000-06-28
IL146807A (en) 2006-10-05
YU92501A (sh) 2004-09-03
NO20016203D0 (no) 2001-12-18
HRP20020088A2 (en) 2005-10-31
BG106251A (en) 2002-08-30
AU5830600A (en) 2001-01-22
US6500867B1 (en) 2002-12-31
CN1168440C (zh) 2004-09-29
JP2008156373A (ja) 2008-07-10
EP1189608A1 (en) 2002-03-27
PE20010399A1 (es) 2001-04-10
PT1189608E (pt) 2003-12-31
MY127685A (en) 2006-12-29
HU230395B1 (hu) 2016-04-28
AR033796A1 (es) 2004-01-07
CA2378469A1 (en) 2001-01-11
ATE245417T1 (de) 2003-08-15
EE200100716A (et) 2003-02-17
JP2003503454A (ja) 2003-01-28
ME00520B (me) 2011-10-10
DK1189608T3 (da) 2003-11-10
FI991485L (fi) 2000-12-31
CZ20014636A3 (cs) 2002-05-15
FI991485A0 (fi) 1999-06-30
BRPI0011867B1 (pt) 2019-01-08
PL197818B1 (pl) 2008-04-30
TR200103763T2 (tr) 2002-04-22
UA75047C2 (en) 2006-03-15
JP4885896B2 (ja) 2012-02-29
HUP0202273A3 (en) 2002-11-28
DE60004052T2 (de) 2004-04-15
SI1189608T1 (en) 2004-04-30
BR0011867A (pt) 2002-03-05
DE60004052D1 (de) 2003-08-28
ITMI20001450A1 (it) 2001-12-28
CZ304416B6 (cs) 2014-04-23
EA200200106A1 (ru) 2002-06-27
NO20110090L (no) 2002-02-25
TWI241187B (en) 2005-10-11
NO330260B1 (no) 2011-03-14
FR2797587A1 (fr) 2001-02-23
EE05473B1 (et) 2011-10-17
CZ303010B6 (cs) 2012-02-29
SK286451B6 (sk) 2008-10-07
ES2203495T3 (es) 2004-04-16
HK1047040B (zh) 2005-04-29
BG65364B1 (bg) 2008-04-30

Similar Documents

Publication Publication Date Title
JP4204783B2 (ja) レボドパ／カルビドパ／エンタカポン医薬製剤
RU2485947C2 (ru) Фармацевтические композиции энтакапона, леводопы и карбидопы с улучшенной биодоступностью
JPH07558B2 (ja) モピダモール製剤
CN103860550A (zh) 左旋多巴/卡比多巴/罗匹尼罗药物制剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060711

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060711

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070405

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20070405

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20070510

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070612

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070913

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20071113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080312

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20080422

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080520

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080417

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080819

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20080924

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20081015

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111024

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4204783

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111024

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121024

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121024

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131024

Year of fee payment: 5

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S201 Request for registration of exclusive licence

Free format text: JAPANESE INTERMEDIATE CODE: R314201

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term